about
Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.The double-edged sword: Neurotoxicity of chemotherapy.Emerging antibody-drug conjugates for treating lymphoid malignancies.Challenges and new frontiers in analytical characterization of antibody-drug conjugates.Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry
P2860
Q30434521-8987EA55-1FD6-4D0E-84DD-0095ACB36ADDQ35223221-857CBA08-3DED-402F-BC61-D5EA56711494Q37738158-020014CE-3149-4EC3-9BF7-886BECE7F97DQ38274890-1120EE55-34BE-46C4-A860-6264969283F6Q38632313-FEB99A6B-6EF7-4ED3-A00D-62D21E58A90FQ52401505-4799D682-5CB3-42EB-9A38-04AE330438BFQ57666042-ED7886F0-AE17-43EB-AFBC-68A6F439ABA8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Brentuximab vedotin in Hodgkin's lymphoma.
@en
type
label
Brentuximab vedotin in Hodgkin's lymphoma.
@en
prefLabel
Brentuximab vedotin in Hodgkin's lymphoma.
@en
P2860
P1476
Brentuximab vedotin in Hodgkin's lymphoma.
@en
P2093
Barbara Pro
Guilherme Fleury Perini
P2860
P304
P356
10.1517/14712598.2012.718328
P407
P50
P577
2012-08-31T00:00:00Z